Literature DB >> 33623890

Framework for identifying drug repurposing candidates from observational healthcare data.

Michal Ozery-Flato1, Yaara Goldschmidt2, Oded Shaham2, Sivan Ravid1, Chen Yanover2.   

Abstract

OBJECTIVE: Observational medical databases, such as electronic health records and insurance claims, track the healthcare trajectory of millions of individuals. These databases provide real-world longitudinal information on large cohorts of patients and their medication prescription history. We present an easy-to-customize framework that systematically analyzes such databases to identify new indications for on-market prescription drugs.
MATERIALS AND METHODS: Our framework provides an interface for defining study design parameters and extracting patient cohorts, disease-related outcomes, and potential confounders in observational databases. It then applies causal inference methodology to emulate hundreds of randomized controlled trials (RCTs) for prescribed drugs, while adjusting for confounding and selection biases. After correcting for multiple testing, it outputs the estimated effects and their statistical significance in each database.
RESULTS: We demonstrate the utility of the framework in a case study of Parkinson's disease (PD) and evaluate the effect of 259 drugs on various PD progression measures in two observational medical databases, covering more than 150 million patients. The results of these emulated trials reveal remarkable agreement between the two databases for the most promising candidates. DISCUSSION: Estimating drug effects from observational data is challenging due to data biases and noise. To tackle this challenge, we integrate causal inference methodology with domain knowledge and compare the estimated effects in two separate databases.
CONCLUSION: Our framework enables systematic search for drug repurposing candidates by emulating RCTs using observational data. The high level of agreement between separate databases strongly supports the identified effects.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.

Entities:  

Keywords:  Parkinson’s disease; causal inference; comparative effectiveness research; drug repositioning; electronic health records

Year:  2020        PMID: 33623890      PMCID: PMC7886555          DOI: 10.1093/jamiaopen/ooaa048

Source DB:  PubMed          Journal:  JAMIA Open        ISSN: 2574-2531


  31 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

3.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 4.  Drug repositioning and repurposing: terminology and definitions in literature.

Authors:  Joris Langedijk; Aukje K Mantel-Teeuwisse; Diederick S Slijkerman; Marie-Hélène D B Schutjens
Journal:  Drug Discov Today       Date:  2015-05-11       Impact factor: 7.851

Review 5.  A survey of current trends in computational drug repositioning.

Authors:  Jiao Li; Si Zheng; Bin Chen; Atul J Butte; S Joshua Swamidass; Zhiyong Lu
Journal:  Brief Bioinform       Date:  2015-03-31       Impact factor: 11.622

6.  Globally efficient non-parametric inference of average treatment effects by empirical balancing calibration weighting.

Authors:  Kwun Chuen Gary Chan; Sheung Chi Phillip Yam; Zheng Zhang
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2015-11-08       Impact factor: 4.488

7.  Caveats for the use of operational electronic health record data in comparative effectiveness research.

Authors:  William R Hersh; Mark G Weiner; Peter J Embi; Judith R Logan; Philip R O Payne; Elmer V Bernstam; Harold P Lehmann; George Hripcsak; Timothy H Hartzog; James J Cimino; Joel H Saltz
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

8.  Age at onset and Parkinson disease phenotype.

Authors:  Gennaro Pagano; Nicola Ferrara; David J Brooks; Nicola Pavese
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

9.  Persistent pain after motor vehicle collision: comparative effectiveness of opioids vs nonsteroidal antiinflammatory drugs prescribed from the emergency department-a propensity matched analysis.

Authors:  Francesca L Beaudoin; Roee Gutman; Roland C Merchant; Melissa A Clark; Robert A Swor; Jeffrey S Jones; David C Lee; David A Peak; Robert M Domeier; Niels K Rathlev; Samuel A McLean
Journal:  Pain       Date:  2017-02       Impact factor: 7.926

10.  Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.

Authors:  Assaf Gottlieb; Chen Yanover; Amos Cahan; Yaara Goldschmidt
Journal:  BMJ Open Diabetes Res Care       Date:  2017-11-30
View more
  7 in total

1.  A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data.

Authors:  Ruoqi Liu; Lai Wei; Ping Zhang
Journal:  Nat Mach Intell       Date:  2021-01-04

Review 2.  Computational drug repurposing based on electronic health records: a scoping review.

Authors:  Nansu Zong; Andrew Wen; Sungrim Moon; Sunyang Fu; Liwei Wang; Yiqing Zhao; Yue Yu; Ming Huang; Yanshan Wang; Gang Zheng; Michelle M Mielke; James R Cerhan; Hongfang Liu
Journal:  NPJ Digit Med       Date:  2022-06-14

3.  Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.

Authors:  Daphna Laifenfeld; Chen Yanover; Michal Ozery-Flato; Oded Shaham; Michal Rosen-Zvi; Nirit Lev; Yaara Goldschmidt; Iris Grossman
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.

Authors:  Suehyun Lee; Seongwoo Jeon; Hun-Sung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-04-13

Review 5.  Machine learning for improving high-dimensional proxy confounder adjustment in healthcare database studies: An overview of the current literature.

Authors:  Richard Wyss; Chen Yanover; Tal El-Hay; Dimitri Bennett; Robert W Platt; Andrew R Zullo; Grammati Sari; Xuerong Wen; Yizhou Ye; Hongbo Yuan; Mugdha Gokhale; Elisabetta Patorno; Kueiyu Joshua Lin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-07-05       Impact factor: 2.732

Review 6.  Artificial intelligence for COVID-19: battling the pandemic with computational intelligence.

Authors:  Zhenxing Xu; Chang Su; Yunyu Xiao; Fei Wang
Journal:  Intell Med       Date:  2021-10-21

Review 7.  Advances in the computational landscape for repurposed drugs against COVID-19.

Authors:  Illya Aronskyy; Yosef Masoudi-Sobhanzadeh; Antonio Cappuccio; Elena Zaslavsky
Journal:  Drug Discov Today       Date:  2021-07-30       Impact factor: 7.851

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.